These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 2857197)

  • 1. Relative selectivity of 6,7-dihydroxy-2-dimethylaminotetralin, N-n-propyl-3-(3-hydroxyphenyl)piperidine, N-n-propylnorapomorphine and pergolide as agonists at striatal dopamine autoreceptors and postsynaptic dopamine receptors.
    Claustre Y; Fage D; Zivkovic B; Scatton B
    J Pharmacol Exp Ther; 1985 Feb; 232(2):519-25. PubMed ID: 2857197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
    Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
    Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential agonist profile of the enantiomers of 3-PPP at striatal dopamine autoreceptors: dependence on extracellular dopamine.
    Clark D; Salah RS; Galloway MP
    Synapse; 1991 Jul; 8(3):169-76. PubMed ID: 1948667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Presynaptic inhibition of dopamine synthesis in rat striatal tissue by enantiomeric mono- and dihydroxyaporphines.
    Booth RG; Baldessarini RJ; Kula NS; Gao Y; Zong R; Neumeyer JL
    Mol Pharmacol; 1990 Jul; 38(1):92-101. PubMed ID: 1973525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacological comparison of 6,7-dihydroxy-2-dimethylaminotetralin (TL-99) and N-n-propyl-3-(3-hydroxyphenyl)piperidine with (3-PPP) selected dopamine agonists.
    Martin GE; Williams M; Haubrich DR
    J Pharmacol Exp Ther; 1982 Nov; 223(2):298-304. PubMed ID: 6813451
    [No Abstract]   [Full Text] [Related]  

  • 6. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
    Seiler MP; Markstein R
    Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects.
    Rugsley TA; Davis MD; Akunne HC; Cooke LW; Whetzel SZ; MacKenzie RG; Shih YH; van Leeuwen DH; DeMattos SB; Georgic LM
    J Pharmacol Exp Ther; 1995 Aug; 274(2):898-911. PubMed ID: 7636753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological profiles of the putative dopamine autoreceptor agonists 3-PPP and TL-99.
    Martin GE; Haubrich DR; Williams M
    Eur J Pharmacol; 1981 Nov; 76(1):15-23. PubMed ID: 7318920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mouse locomotor activity: an in vivo test for dopamine autoreceptor activation.
    Martin GE; Bendesky RJ
    J Pharmacol Exp Ther; 1984 Jun; 229(3):706-11. PubMed ID: 6144790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo.
    Galloway MP; Wolf ME; Roth RH
    J Pharmacol Exp Ther; 1986 Mar; 236(3):689-98. PubMed ID: 3081705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological profile of dopamine receptor agonists as studied by brain dialysis in behaving rats.
    Imperato A; Tanda G; Frau R; Di Chiara G
    J Pharmacol Exp Ther; 1988 Apr; 245(1):257-64. PubMed ID: 3258912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    Arnerić SP; Long JP; Williams M; Goodale DB; Mott J; Lakoski JM; Gebhart GF
    J Pharmacol Exp Ther; 1983 Jan; 224(1):161-70. PubMed ID: 6401334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine agonists at repeated "autoreceptor-selective" doses: effects upon the sensitivity of A10 dopamine autoreceptors.
    Jeziorski M; White FJ
    Synapse; 1989; 4(4):267-80. PubMed ID: 2603146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum.
    Hársing LG; Vizi ES
    Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The search for selective dopaminergic autoreceptor agonists.
    Hjorth S; Carlsson A; Clark D; Svensson K; Wikström H; Sanchez D; Lindberg P; Hacksell U; Arvidsson LE; Johansson A; Nilsson JL
    J Neural Transm Suppl; 1983; 18():131-7. PubMed ID: 6576112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between endogenous dopamine and dopamine agonists at release modulatory receptors: multiple effects of neuronal uptake inhibitors on transmitter release.
    Hoffmann IS; Talmaciu RK; Cubeddu LX
    J Pharmacol Exp Ther; 1986 Aug; 238(2):437-46. PubMed ID: 2942676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurochemical and behavioral evidence that Ro 41-9067 is a selective presynaptic dopamine receptor agonist.
    Nisoli E; Tonello C; Imhof R; Scherschlicht R; da Prada M; Carruba MO
    J Pharmacol Exp Ther; 1993 Jul; 266(1):97-105. PubMed ID: 8101225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Degree of selectivity of pergolide as an agonist at presynaptic versus postsynaptic dopamine receptors: implications for prevention or treatment of tardive dyskinesia.
    Fuller RW; Clemens JA; Hynes MD
    J Clin Psychopharmacol; 1982 Dec; 2(6):371-5. PubMed ID: 7174859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?
    Fowler CJ; Thorell G; Andersson M; Magnusson O
    Naunyn Schmiedebergs Arch Pharmacol; 1985 Oct; 331(1):12-9. PubMed ID: 2866447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.
    Koch SW; Koe BK; Bacopoulos NG
    Eur J Pharmacol; 1983 Sep; 92(3-4):279-83. PubMed ID: 6138267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.